Asenapine

Small molecule

Also known as SCH 900274

Approvedregulatory verdict

Evidence outlook

Approved: Schizophrenia, Bipolar Disorder

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (3)
US
  • Acute monotherapy of manic or mixed episodes, in adults and pediatric patients 10 to 17 years of age
  • Adjunctive treatment to lithium or valproate in adults
Product first approved 2009Outside this platform's coverageFDA label
EU
  • Sycrest is indicated for the treatment of moderate to severe manic episodes associated with bipolar I disorder in adults.
Product first approved 2010EMA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (32)
Bipolar Disorder
NCT01396291 · Forest Laboratories
2011-12 – 2015-06 · Bipolar 1 Disorder
What this study did
NCT01395992 · Forest Laboratories
2012-04 – 2015-01 · Bipolar I Disorder
What this study did
NCT01349907 · Organon and Co
2011-06-16 – 2014-09-05 · Bipolar Disorder
What this study did
NCT00764478 · Organon and Co
2012-04-06 – 2014-05-28 · Bipolar 1 Disorder
What this study did
NCT01244815 · Organon and Co
2011-06-16 – 2013-09-17 · Bipolar Disorder, Pediatric
What this study did
NCT00145509 · Organon and Co
2005-08 – 2007-12 · Bipolar Disorder
What this study did
NCT00159783 · Organon and Co
2005-07 – 2007-04 · Bipolar Disorder
What this study did
NCT00145470 · Organon and Co
2005-06-02 – 2007-03-22 · Bipolar Disorder
What this study did
NCT00143182 · Organon and Co
2005-01-07 – 2006-06-28 · Bipolar Disorder
What this study did
Schizophrenia
NCT01142596 · Organon and Co
2010-05-25 – 2015-04-22 · Schizophrenia
What this study did
NCT01617200 · Forest Laboratories
2012-12 – 2015-03 · Schizophrenia
What this study did
NCT01617187 · Organon and Co
2012-12-04 – 2014-09-09 · Schizophrenia
What this study did
NCT01098110 · Organon and Co
2010-05-25 – 2014-04-14 · Schizophrenia
What this study did
NCT01190267 · Organon and Co
2010-09-28 – 2013-10-07 · Schizophrenia, Paranoid, Schizophrenia, Disorganized, Schizophrenia, Undifferentiated
What this study did
NCT01190254 · Organon and Co
2010-09-28 – 2013-04-01 · Schizophrenia, Paranoid, Schizophrenia, Disorganized, Schizophrenia, Undifferentiated
What this study did
NCT00150176 · Organon and Co
2005-04 – 2008-07 · Schizophrenia
What this study did
NCT00265343 · Organon and Co
2005-12 – 2008-01 · Schizophrenia
What this study did
NCT00156065 · Organon and Co
2005-09 – 2007-10 · Schizophrenia
What this study did
NCT00212836 · Organon and Co
2005-04-21 – 2007-08-02 · Schizophrenia
What this study did
NCT00156091 · Organon and Co
2005-04 – 2007-06 · Schizophrenia
What this study did
NCT00156104 · Organon and Co
2005-07-01 – 2006-09-16 · Schizophrenia
What this study did
NCT00156117 · Organon and Co
2005-05-12 – 2006-05-30 · Schizophrenia
What this study did
NCT00151424 · Organon and Co
2005-02-15 – 2006-02-06 · Schizophrenia
What this study did
Other / comorbidity
NCT00281320 · Organon and Co
2006-02 – 2008-12 · Psychosis
What this study did
Phase 2/3 (1)
Schizophrenia
NCT02072954 · Amneal Pharmaceuticals, LLC
2013-11 – 2014-06 · Schizophrenia
What this study did
Phase 2 (3)
Schizophrenia
Other / comorbidity
NCT01807741 · University of Cincinnati
2013-09 – 2017-07 · Bipolar Depression
What this study did
Phase 1 (2)
Bipolar Disorder
NCT01948024 · Sun Pharmaceutical Industries Limited
2013-07 – 2013-08 · Schizophrenia, Bipolar Disorder
What this study did
NCT01206517 · Organon and Co
2010-07-18 – 2011-08-04 · Schizophrenia, Bipolar I Disorder
What this study did
Phase 4 (6)
Bipolar Disorder
NCT01460290 · University Hospitals Cleveland Medical Center
2011-10 – 2014-03 · Bipolar Disorder
What this study did
Schizophrenia
NCT01968161 · Centre de Recherche de l'Institut Universitaire en Santé Mentale de Québec
2013-10 – 2014-03 · Schizophrenia and Disorders With Psychotic Features, Disorders
What this study did
NCT01549041 · Duke University
2012-04 – 2013-11 · Schizophrenia
What this study did
Other / comorbidity
NCT01587118 · Lori Davis, MD
2012-06 – 2016-07 · Posttraumatic Stress Disorder
What this study did
NCT01670019 · Duke University
2012-10 – 2014-06 · Major Depressive Disorder Without Psychotic Features
What this study did
NCT01400113 · Unity Health Toronto
2012-04 – 2012-12 · Agitation
What this study did

Competitive landscape

This mechanism is crowded: 24 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Bipolar Disorder: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Asenapine: this drugApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify Maintena)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D2/D3 and serotonin 5-HT1A receptor, Dopamine D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify)ApprovedSmall moleculeDopamine D2/D3 and serotonin 5-HT1A receptornot yet gradedNo reviewed efficacy summary in this indication
Cariprazine (Vraylar)ApprovedSmall moleculeDopamine D3/D2 receptor (partial agonist)not yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote ER)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote)ApprovedSmall moleculeGABAergic neurotransmissionPartial signalFeatured results are non-efficacy only in this race
Iloperidone (Fanapt)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
LamotrigineApprovedSmall moleculeVoltage-gated sodium channelnot yet gradedNo reviewed efficacy summary in this indication
Milsaperidone (VHX-896)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Weak signalNo reviewed efficacy summary in this indication
Olanzapine (Zyprexa)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Olanzapine / Samidorphan (Lybalvi)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist); mu-opioid receptor (antagonist)Reliable signalNo reviewed efficacy summary in this indication
Quetiapine (Seroquel XR)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Quetiapine (Seroquel)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Risperdal Consta)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Risperdal)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Rykindo)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Risperidone (Uzedy)ApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
ZiprasidoneApprovedSmall moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)not yet gradedNo reviewed efficacy summary in this indication
Dexmedetomidine (Igalmi)Phase 3Small moleculeAlpha-2 adrenergic receptor (agonist)Reliable signalNo reviewed efficacy summary in this indication
Loxapine (Adasuve)Phase 3Small moleculeDopamine D2 and serotonin 5-HT2A receptors (antagonist)Partial signalNo reviewed efficacy summary in this indication
Xanomeline / Trospium Chloride (Cobenfy)Phase 3Small moleculeMuscarinic M1/M4 receptor (agonist/antagonist combination)not yet gradedNo reviewed efficacy summary in this indication
ALTO-100Phase 2Small moleculeFirst-in-class oral small molecule neural plasticity enhancernot yet gradedNo reviewed efficacy summary in this indication
BrenipatidePhase 2PeptideGLP-1/GIP receptor (dual)not yet gradedNo reviewed efficacy summary in this indication
ElunetiromPhase 2Small moleculeThyroid hormone receptor-betanot yet gradedNo reviewed efficacy summary in this indication
IcalcaprantPhase 2Small moleculeKappa-opioid receptor (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
Lithium Salicylate / L-Proline (AL001)Phase 1/2Small molecule—not yet gradedNo reviewed efficacy summary in this indication
ABBV-1042
Phase 1(overall)
Small moleculeMuscarinic M4 receptornot yet gradedNo reviewed efficacy summary in this indication
Aripiprazole (Abilify MyCite)DiscontinuedCombinationDopamine D2 and serotonin 5-HT1A receptors (partial agonist); serotonin 5-HT2A receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.